Melatonin supplementation, hyperprolactinemia, and incident heart failure: A proposed prolactin-mediated pathway for cardiovascular risk.

Christos Savvidis, Costas Thomopoulos, Ioannis Ilias
{"title":"Melatonin supplementation, hyperprolactinemia, and incident heart failure: A proposed prolactin-mediated pathway for cardiovascular risk.","authors":"Christos Savvidis, Costas Thomopoulos, Ioannis Ilias","doi":"10.5493/wjem.v16.i2.120754","DOIUrl":null,"url":null,"abstract":"<p><p>The problem of heart failure (HF) is complicated and is continuously growing, making the need for novel solutions critical. The role of melatonin, widely used as an over-the-counter medication for sleep disorders, has been historically researched for its cardioprotective actions based on its established antioxidant properties. Recent preliminary evidence, however, points to a possibly alarming association: A statistically significant increased risk of new onset HF, HF requiring hospitalization, and all-cause mortality was observed in association with long-term melatonin therapy (one year or longer in duration), in adult patients suffering from insomnia. However, these were reported in a single, as-yet unpublished conference abstract that has not undergone peer review or independent validation. This hypothesis-generating observation warrants careful investigation of possible mechanisms. In this article we speculatively propose a plausible - but as yet unconfirmed - mechanistic pathway mediated through prolactin (PRL). Melatonin may increase the release of PRL through its modulation of hypothalamic dopaminergic neurons, though whether this effect is sustained with long-term use remains an unresolved critical knowledge gap. This is particularly relevant given that peripartum cardiomyopathy, a dangerous, pregnancy-related variant of HF, has as its central mechanism the cardiotoxic effect of a cytotoxic 16-kDa fragment of PRL. We hypothesize that chronic exogenous melatonin use might - if it were shown to sustain hyperprolactinemia - provide excess PRL that could theoretically be cleaved to the cardiotoxic 16-kDa fragment in patients with pre-existing oxidative stress and cardiovascular risk factors, in a manner analogous to peripartum cardiomyopathy. This speculative mechanism should be tested in prospective mechanistic and clinical studies, with appropriate adjustment for confounders including insomnia severity.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"16 2","pages":"120754"},"PeriodicalIF":0.0000,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13323919/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of experimental medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5493/wjem.v16.i2.120754","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The problem of heart failure (HF) is complicated and is continuously growing, making the need for novel solutions critical. The role of melatonin, widely used as an over-the-counter medication for sleep disorders, has been historically researched for its cardioprotective actions based on its established antioxidant properties. Recent preliminary evidence, however, points to a possibly alarming association: A statistically significant increased risk of new onset HF, HF requiring hospitalization, and all-cause mortality was observed in association with long-term melatonin therapy (one year or longer in duration), in adult patients suffering from insomnia. However, these were reported in a single, as-yet unpublished conference abstract that has not undergone peer review or independent validation. This hypothesis-generating observation warrants careful investigation of possible mechanisms. In this article we speculatively propose a plausible - but as yet unconfirmed - mechanistic pathway mediated through prolactin (PRL). Melatonin may increase the release of PRL through its modulation of hypothalamic dopaminergic neurons, though whether this effect is sustained with long-term use remains an unresolved critical knowledge gap. This is particularly relevant given that peripartum cardiomyopathy, a dangerous, pregnancy-related variant of HF, has as its central mechanism the cardiotoxic effect of a cytotoxic 16-kDa fragment of PRL. We hypothesize that chronic exogenous melatonin use might - if it were shown to sustain hyperprolactinemia - provide excess PRL that could theoretically be cleaved to the cardiotoxic 16-kDa fragment in patients with pre-existing oxidative stress and cardiovascular risk factors, in a manner analogous to peripartum cardiomyopathy. This speculative mechanism should be tested in prospective mechanistic and clinical studies, with appropriate adjustment for confounders including insomnia severity.

褪黑素补充、高催乳素血症和心力衰竭:一种拟议的催乳素介导的心血管风险途径。
心力衰竭(HF)的问题是复杂的,并不断增长,使得需要新的解决方案至关重要。褪黑激素被广泛用作治疗睡眠障碍的非处方药物,基于其已建立的抗氧化特性,人们一直在研究其保护心脏的作用。然而,最近的初步证据指出了一个可能令人担忧的关联:在患有失眠症的成年患者中,长期褪黑素治疗(持续时间一年或更长)会显著增加新发HF、HF需要住院治疗和全因死亡率的风险。然而,这些都是在一个单一的,尚未发表的会议摘要中报告的,没有经过同行评审或独立验证。这种产生假设的观察值得对可能的机制进行仔细的调查。在本文中,我们推测提出了一种看似合理但尚未证实的机制途径,即通过催乳素(PRL)介导。褪黑素可能通过调节下丘脑多巴胺能神经元来增加PRL的释放,尽管这种作用是否会随着长期使用而持续,仍然是一个尚未解决的关键知识缺口。考虑到围产期心肌病是一种危险的、与妊娠相关的心衰变体,其核心机制是PRL的细胞毒性16 kda片段的心脏毒性作用,这一点尤为重要。我们假设慢性外源性褪黑素使用可能——如果它被证明可以维持高泌乳素血症——提供过量的PRL,理论上可以在存在氧化应激和心血管危险因素的患者中裂解为心脏毒性的16-kDa片段,类似于围产期心肌病。这种推测的机制应该在前瞻性机制和临床研究中进行测试,并适当调整包括失眠严重程度在内的混杂因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书